Article
Oncology
Ahmet Bilici, Sinan Koca, Mustafa Karaagac, Sabin Goktas Aydin, Emrah Eraslan, Muhammed Ali Kaplan, Birol Ocak, Sema Sezgin Goksu, Semra Paydas, Fahri Akgul, Sumeyye Derin, Yakup Ergun, Emre Yekeduz, Cihan Erol, Deniz Tataroglu Ozyukseler, Atike Gokcen Demiray, Mustafa Karaca, Zeynep Gulsum Guc, Serkan Menekse, Havva Yesil Cinkir, Ozge Gumusay, Abdullah Sakin, Ozlem Ozkul, Hacer Demir, Dilek Erdem, Mehmet Besiroglu, Olcun Umit Unal, Ramazan Acar, Lokman Koral, Suleyman Sahin, Teoman Sakalar, Aykut Bahceci, Ahmet Ozveren, Ulug Mutlu Gunaydin, Mehmet Metin Seker, Veli Sunar, Pinar Dal, Mehmet Artac, Serdar Turhal
Summary: This study retrospectively analyzed the medical records of patients with non-adipocytic metastatic soft tissue sarcoma treated with pazopanib in 37 oncology clinics in Turkey. The results showed that pazopanib is effective and well-tolerated in the treatment of this disease, with better outcomes observed when used earlier and in patients with good performance status.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
William G. J. Kerrison, Alexander T. J. Lee, Khin Thway, Robin L. Jones, Paul H. Huang
Summary: Immunotherapy in soft tissue sarcoma has become a popular and promising therapeutic strategy, with immune checkpoint inhibitors showing effectiveness in certain subtypes. Combination therapies have also shown enhanced response rates.
Article
Pharmacology & Pharmacy
Marie-Sophie Minot-This, Pascaline Boudou-Rouquette, Anne Jouinot, Sixtine de Percin, David Balakirouchenane, Nihel Khoudour, Camille Tlemsani, Jonathan Chauvin, Audrey Thomas-Schoemann, Francois Goldwasser, Benoit Blanchet, Jerome Alexandre
Summary: This study aimed to define the specific threshold of Pazopanib (PAZ) trough concentration associated with better progression-free survival in soft tissue sarcoma patients. The results showed that PAZ C-min < 27 mg/L was independently associated with a risk of progression at 3 months, and a higher average of PAZ C-min was associated with a higher risk of grade 3-4 toxicities.
Article
Oncology
Do Weon Lee, Han-Soo Kim, Ilkyu Han
Summary: The study found that actual 5-year survival in stage III soft tissue sarcoma patients is associated with tumor size, histological grade, and ASA score. Nevertheless, the majority of long-term survivors still exhibit factors of poor prognosis.
Review
Pharmacology & Pharmacy
Tomoki Nakamura, Akihiro Sudo
Summary: Trabectedin is a safe and effective therapeutic option for patients with advanced STS. While it may be effective as first-line treatment in selected patients, doxorubicin remains the preferred choice for locally advanced or metastatic STS.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Giuseppe Corona, Emanuela Di Gregorio, Angela Buonadonna, Davide Lombardi, Simona Scalone, Agostino Steffan, Gianmaria Miolo
Summary: This pharmacometabolomics study identified pre-dose plasma metabolomics signatures that can explain individual variations in trabectedin pharmacokinetics and overall clinical response to treatment in patients with metastatic soft tissue sarcoma. The findings suggest that pre-dose metabolomics can be utilized to uncover the underlying causes of pharmacokinetic variability of trabectedin and identify patients who are most likely to benefit from this treatment.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pathology
David J. Papke, Brendan C. Dickson, Lynette Sholl, Christopher D. M. Fletcher
Summary: In this article, a previously unrecognized tumor entity called pseudoendocrine sarcoma is described, which has distinctive pathological features and clinical behavior. This rare tumor has a predilection for paravertebral soft tissue in older adults and has an uncertain cell lineage. Despite its bland morphology, it is considered an intermediate-grade sarcoma.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2022)
Article
Oncology
Tomoki Nakamura, Tomohito Hagi, Kunihiro Asanuma, Akihiro Sudo
Summary: The study found that lymphocyte to C-reactive protein ratio (LCR) can predict disease-specific survival (DSS) and event-free survival (EFS) in patients with soft tissue sarcoma (STS). Patients with lower LCR had worse survival than those with higher LCR.
Article
Oncology
Tom Wei-Wu Chen, Ruru Chun-Ju Chiang, Alex Le Cesne, Yu-Chun Hsieh, Antoine Italiano, Ya-Wen Yang, Nicolas Penel, Wen-Chung Lee, Emmanuelle Bompas, Thibaud Valentin, Philippe Anract, Nelly Firmin, Florence Duffaud, Ann-Lii Cheng, Francoise Ducimetiere, K. Arnold Chan, Jean-Yves Blay
Summary: The study found significant differences in the incidence and clinical characteristics of soft tissue sarcoma (STS) among different geographic and ethnic populations, suggesting that geographic and ethnic factors may play a crucial role in the pathogenesis of STS.
Article
Oncology
Angela Buonadonna, Simona Scalone, Davide Lombardi, Arianna Fumagalli, Alessandra Guglielmi, Chiara Lestuzzi, Jerry Polesel, Vincenzo Canzonieri, Stefano Lamon, Petros Giovanis, Sara Gagno, Giuseppe Corona, Maurizio Mascarin, Claudio Belluco, Antonino De Paoli, Gianpiero Fasola, Fabio Puglisi, Gianmaria Miolo
Summary: This study investigates the combination of non-pegylated liposomal doxorubicin (NPLD) with ifosfamide as a first-line treatment for advanced/metastatic soft tissue sarcoma (STS). The results show a significant overall response rate and disease control rate, indicating that this drug combination is effective and well-tolerated. This finding provides a basis for further research on the clinical application of this drug combination in STS.
Article
Oncology
Jie Liu, Yao-Tiao Deng, Yu Jiang
Summary: The study found that switch maintenance therapy with anlotinib is a promising strategy for the treatment of patients with unresectable or metastatic STS who have benefited from chemotherapy. Toxicities were manageable, and prospective clinical trials are needed to confirm this finding.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Biochemistry & Molecular Biology
Timur I. Fetisov, Sofya A. Khazanova, Polina A. Shtompel, Ekaterina S. Trapeznikova, Victoria Y. Zinovieva, Valeria I. Marshall, Anastasia A. Lovenger, Dmitriy V. Rogozhin, Tararykova A. Anastasia, Beniamin Yu. Bokhyan, Gennady A. Belitsky, Marianna G. Yakubovskaya, Kirill I. Kirsanov
Summary: Treatment of highly malignant soft tissue sarcomas (STSs) involves multicomponent therapy, but personalized selection of chemotherapy is lacking. In this study, in vitro chemosensitivity/resistance assays (CSRAs) were used to predict STS chemoresistance. Results showed that certain cancer histotypes had higher resistance to specific drugs and combinations, and the CSRAs were correlated with clinical responses and survival outcomes. CSRAs can assist physicians in avoiding ineffective treatments and aid researchers in developing new STS drugs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Xin-Yu Ke, Ye Chen, Valarie Yu-Yan Tham, Ruby Yu-Tong Lin, Pushkar Dakle, Kassoum Nacro, Mark Edward Puhaindran, Peter Houghton, Angela Pang, Victor Kwanmin Lee, Ling-Wen Ding, Sigal Gery, Jeffrey Hill, Leilei Chen, Liang Xu, H. Phillip Koeffler
Summary: Depletion of MNK1/2 suppresses growth of soft tissue sarcoma cells, and a novel MNK inhibitor ETC-168 shows significant antiproliferative efficacy. Combination of ETC-168 with MCL1 inhibitor exerts synergistic antiproliferative activity against STS cells. This study highlights the potential clinical translation of MNK inhibitors for the treatment of soft tissue sarcoma.
Article
Oncology
Kenji Nakano, Naoki Fukuda, Yasuyoshi Sato, Tetsuya Urasaki, Akihiro Ohmoto, Xiaofei Wang, Naomi Hayashi, Hirotaka Suto, Shohei Udagawa, Ryosuke Oki, Mayu Yunokawa, Makiko Ono, Junichi Tomomatsu, Yusuke Minami, Keiko Hayakawa, Taisuke Tanizawa, Keisuke Ae, Seiichi Matsumoto, Shunji Takahashi
Summary: This study retrospectively analyzed the characteristics, chemotherapy details, and prognoses of patients with retroperitoneal/intra-abdominal soft tissue sarcoma and extremities/trunk soft tissue sarcoma who received systemic chemotherapy in a recurrent/metastatic setting, revealing similar outcomes in salvage chemotherapy between the two cohorts.
Article
Oncology
Paulina M. Gutkin, Rie von Eyben, Alexander Chin, Sarah S. Donaldson, Justin Oh, Alice Jiang, Kristen N. Ganjoo, Raffi S. Avedian, Matias Bruzoni, Robert J. Steffner, Everett J. Moding, Susan M. Hiniker
Summary: This study analyzed patients with metastatic sarcoma and found that those treated with SBRT had excellent local control and lower local recurrence rates compared to surgical management.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)